TFO
BTAI icon

Tarbox Family Office’s BioXcel Therapeutics BTAI Stock Holding History

Tarbox Family Office’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$1K – 1083
2021
Q4 		$1K Buy
+4
New +$1.72K ﹤0.01% 981

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tarbox Family Office's BTAI Position: Q1 2022 in Review

Tarbox Family Office sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 4 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in BTAI in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

  • Tarbox Family Office reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tarbox Family Office sold 4 BioXcel Therapeutics shares in Q1 2022, an estimated $1K.
  • Tarbox Family Office first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 1 quarter.
  • Tarbox Family Office's BioXcel Therapeutics position peaked at $1K in Q4 2021.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on Tarbox Family Office's 13F filing for Q1 2022, filed 25 Apr 2022.